Alliances

Found 54,227 articles

• Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting

  4/24/2023

  Viatris Inc. and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27.

• SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

  4/21/2023

  SciSparc Ltd. announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

• Nano Pharmaceuticals Labs Partners with PLT Health Solutions to Expand its zümXR Targeted Release Ingredients Globally

  4/20/2023

  PLT Health Solutions, Inc. announced that it has partnered with Nano Pharmaceuticals Labs, LLC ( Denver, CO ) to market its portfolio of targeted release ingredients on a global basis.

• TPG and AmerisourceBergen to Acquire Leading Specialty Practice Network OneOncology From General Atlantic

  4/20/2023

  TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced that they have agreed to acquire OneOncology, a network of leading oncology practices, from General Atlantic, a leading global growth equity firm.

• Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

  4/20/2023

  Cantex Pharmaceuticals, Inc. and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the initiation of a randomized double-blind, placebo-controlled, multicenter, phase 2/3 clinical study to evaluate the safety and efficacy of azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.

• Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

  4/20/2023

  Twist Bioscience Corporation today announced a collaboration with Astellas Pharma Inc.

• Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

  4/20/2023

  This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases.

• Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation

  4/20/2023

  Augmedix today announced a partnership with HCA Healthcare, Inc. (NYSE: HCA), one of the nation's leading healthcare providers, to accelerate development of technology that aims to transform the way patient care is documented in the acute care setting.

• Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

  4/20/2023

  Blue Water Vaccines Inc. today announced the signing of an Asset Purchase Agreement (the “Agreement”) with Veru Inc. (“Veru”) for the purchase of ENTADFI®.

• Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound GelProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care market

  4/20/2023

  Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) for its coactiv+™ Antimicrobial Wound Gel in the United States wound care market.

• EMIT IMAGING Collaborates with MIT Koch Institute for Integrative Cancer Research to Enhance Cryo-Fluorescence Tomography Technology

  4/20/2023

  EMIT IMAGING, Inc. (“EMIT”), the leader in Cryo-Fluorescence Tomography (CFT), is proud to announce a project with the MIT Koch Institute for Integrative Cancer Research to enhance EMIT’s novel 3D imaging technology.

• Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science

  4/20/2023

  Moderna, Inc. and IBM (NYSE:IBM) today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science.

• Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change

  4/20/2023

  Abbott announced that it is partnering with the Climate Amplified Disease and Epidemics consortium, a group of more than 100 global scientists in public health agencies, academia and industry focused on using data science technology and diagnostic testing to assess and potentially mitigate the impact climate change has on disease outbreaks.

• Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics

  4/20/2023

  Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of novel mRNA-based cancer therapeutics that utilizes Samyang's proprietary drug delivery technology.

• LeMaitre to Distribute Aziyo Biologics’ Cardiovascular Patches

  4/20/2023

  LeMaitre Vascular, Inc., a provider of vascular devices, implants and services, announced it has entered into an agreement with Aziyo Biologics, Inc. to become the exclusive distributor of Aziyo’s cardiovascular patches in the United States.

• Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio

  4/20/2023

  Aziyo Biologics, Inc., a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, announced it has entered into a distribution agreement with LeMaitre Vascular, Inc., a provider of vascular devices, implants and services.

• Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO 2023

  4/20/2023

  Luxa Biotechnology today announced the company will provide an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in New Orleans from April 23– 27, 2023.

• Asahi Kasei Bioprocess America and GeminiBio Enter Strategic Partnership to Advance Application of Inline Buffer Formulation and Streamline Biopharmaceutical Manufacturing Processes

  4/19/2023

  Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation in the biopharmaceutical industry.

• Ancora Heart Inc. and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patients

  4/19/2023

  Ancora Heart, Inc. and egnite, Inc. today announced a strategic partnership to accelerate clinical trial enrollment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System.

• Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology

  4/19/2023

  Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) announced today a strategic partnership with Vectara, a company specializing in innovative Natural Language Understanding (NLU) technologies, to accelerate the development of novel therapies for the treatment of cancer, infectious disease, and aging.